Adjuvant therapy for non-small cell lung cancer.
França LB, Oliveira MA, Small IÁ, Zukin M, Araújo LH.
França LB, et al.
J Bras Pneumol. 2011 May-Jun;37(3):354-9. doi: 10.1590/s1806-37132011000300012.
J Bras Pneumol. 2011.
PMID: 21755191
Free article.
English, Portuguese.
OBJECTIVE: Adjuvant chemotherapy is recommended for most patients submitted to resection due to non-small cell lung cancer (NSCLC) staged as II or IIIA. However, although various chemotherapy regimens that include cisplatin have been used in phase III trials, the best choi …
OBJECTIVE: Adjuvant chemotherapy is recommended for most patients submitted to resection due to non-small cell lung cancer (NSCLC) st …